Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Huiqiang Huang
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02878278CT.gov Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epstein-Barr Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tucidinostat (this asset) | Huiqiang Huang | P2 | CCC · 53 |
| Rituximab | Jennifer Amengual | P2 | BB |
| L-Dep | Beijing Friendship Hospital | P3 | B |
| Bortezomib | Massachusetts General Hospital | P2 | B |
| Nivolumab | National Cancer Institute (NCI) | P2 | CCC |
| Baltaleucel-T | Cell Medica Ltd | P2 | CCC |
| Tabelecleucel | Pierre Fabre Medicament | P2 | CCC |
| Adenovirus Specific T- Lymphocytes | Jessie L. Alexander | P1/2 | CCC |
| Brentuximab Vedotin | Northwestern University | P1/2 | CCC |
+8 more in the Epstein-Barr Virus Infection cohort
Other indications for Tucidinostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Extranodal Nasal NK/T Cell Lymphoma | — | P4 | BB · 70 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BB · 69 |
| Acute Lymphoblastic Leukemia | — | P2/3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tucidinostat in Epstein-Barr Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tucidinostat-epstein-barr-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →